177Lu-PSMA-I&T
177Lu-PSMA-I&T is a second PSMA radioligand, chemically different from Pluvicto, that has passed two phase 3 trials on progression but has not yet shown a survival benefit.
Overview
SPLASH (Lantheus PNT2002, ESMO 2024): rPFS 9.5 vs 6.0 months (HR 0.71) vs ARPI switch in taxane-naive mCRPC; interim OS HR 1.11 (immature, crossover). ECLIPSE (Curium, 7.4 GBq × 6): met rPFS endpoint vs ARPI in the same setting; OS maturing; FDA submission plan pending. Curium's Japanese registrational trial with PeptiDream started February 2026. Widely used off-protocol in Germany and Australia.
- PSMA / SSTR-positive cell
Urea-based PSMA ligand with DOTAGA chelator carrying 177Lu; beta emission. Connects to PSMA.
- PSMA / SSTR-positive cell
1.177Lu-PSMA-I&T binds PSMA on the cancer cell or is taken up by it.
Compare all products across the US, EU, UK, Japan, China and Australia →
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"177Lu-PSMA-I&T" OR ABSTRACT:"177Lu-PSMA-I&T" OR TITLE:"PNT2002 Lantheus" OR ABSTRACT:"PNT2002 Lantheus" OR TITLE:"Curium 177Lu-PSMA-I&T" OR ABSTRACT:"Curium 177Lu-PSMA-I&T") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about 177Lu-PSMA-I&T, not a curated reading list.
Similar pages
not linked directly; found by shared links- PersonThomas A. Hope
Shares PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonRahul Aggarwal
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- CompanyPOINT Biopharma
Shares Lutetium-177 PNT2002, PSMA, Radioligand therapy (beta emitters), Prostate cancer.
- PersonMichael J. Morris
Shares PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonJohannes Czernin
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonMichael Hofman
Shares PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- TrialA Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Shares Metastatic castration-resistant prostate cancer, PSMA, Prostate cancer, Lutetium-177.
- AgentLocametz (kit for Ga-68 gozetotide)
Shares PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, PSMA, PSMA PET, Radioligand therapy (beta emitters).